May 22, 2020: The Week in Cancer News
Metastatic prostate cancer incidence rose after changes to prostate cancer screening guidelines.
Progress Against Cancer
Metastatic prostate cancer incidence rose after changes to prostate cancer screening guidelines.
The FDA has expanded the use of the PARP-targeted therapeutic olaparib to include the treatment of certain patients with metastatic prostate cancer. The U.S. Food and Drug Administration (FDA) has expanded the use of...
The FDA has approved a new molecularly targeted therapeutic for treating certain patients who have advanced gastrointestinal stromal tumors.
Findings from a recent study suggest that patients may experience a greater occurrence of infections in the years preceding a cancer diagnosis.
The FDA has expanded the use of a molecularly targeted therapeutic to include the treatment of certain patients with prostate cancer.
The FDA has approved a combination of the immunotherapeutics nivolumab and ipilimumab to treat certain patients with metastatic lung cancer.
The FDA has expanded the use of an immunomodulatory therapeutic to include the treatment of adults who have Kaposi sarcoma.
A study indicates that children with cancer are not at increased risks of severe cases of COVID-19, and more news of the week from Cancer Today.
In the United States, nearly 24,000 people are estimated to receive a brain or nervous system cancer diagnosis in 2020. Even though these cancers represent only about 1 percent of all new cancer cases, brain and other nervous system cancers are the ninth leading cause of cancer-related mortality.
Epithelial ovarian cancer is by far the most common ovarian cancer subtype, accounting for 90 percent of ovarian cancers. The complex genetic heterogeneity of this disease makes treatment particularly difficult. While the introduction of PARP inhibitors to treat ovarian cancers has been a major advancement, only the approximately 50 percent of epithelial ovarian cancers that exhibit defective DNA repair via homologous recombination are potentially responsive to PARP inhibition. Moreover, the development of therapeutic resistance remains a challenge.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More